Physician
Hasham & Associates MD, P.A.
Hasham & Associates MD, P.A. was paid $3.07M by Medicaid between Jan 2018 and Mar 2024, across 67 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 39% of everything it billed.
33Billing provider infoHASHAM & ASSOCIATES MD, P.A.
IRVING, TX 75061
IRVING, TX 75061
33aNPI1144623828assigned 10/08/2014
33bProvider typeInternal Medicine Physician
28Total paid$3.07M
24GClaims165,465
24DCodes billed67
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other Internal Medicine Physician providers in Texas
Rank by total paid#15 of 1,028
Median peer was paid$10K
This provider vs. median295×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118 | $4K | |
| 2019 | 102 | $3K | |
| 2020 | 6,151 | $103K | |
| 2021 | 43,793 | $865K | |
| 2022 | 52,099 | $1.08M | |
| 2023 | 51,533 | $825K | |
| 2024incomplete | 11,669 | $184K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 39% | 35,138 | 28,406 | $1.21M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.4% | 6,669 | 6,171 | $259K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.9% | 3,623 | 3,296 | $242K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.9% | 16,166 | 7,588 | $210K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.5% | 2,499 | 2,248 | $169K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.5% | 2,286 | 2,024 | $138K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.0% | 14,875 | 7,251 | $123K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 7,601 | 7,171 | $99K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.2% | 1,257 | 1,140 | $97K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 1,834 | 1,693 | $92K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 557 | 510 | $73K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.0% | 1,142 | 1,083 | $62K |
55 more codes
| 87807 | 1.2% | 3,510 | $37K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.1% | 4,809 | $34K |
| 99050 | <1% | 1,901 | $27K | |
| 90461 | <1% | 5,681 | $26K | |
| 92587 | <1% | 4,780 | $25K | |
| 99381 | <1% | 477 | $24K | |
| 85018 | <1% | 8,033 | $15K | |
| 99383 | <1% | 172 | $14K | |
| 80061 | Lipid panel | <1% | 1,148 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 152 | $10K |
| 83655 | <1% | 1,113 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 725 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,227 | $8K |
| 97802 | <1% | 2,744 | $6K | |
| 92551 | <1% | 608 | $6K | |
| 99401 | <1% | 2,337 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 86 | $4K |
| 99382 | <1% | 46 | $4K | |
| 99384 | <1% | 33 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 296 | $3K |
| 82947 | <1% | 987 | $3K | |
| 99000 | <1% | 898 | $3K | |
| 96127 | <1% | 1,272 | $2K | |
| 69210 | <1% | 46 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 38 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,858 | $945.00 |
| 90649 | <1% | 93 | $560.00 | |
| 81002 | <1% | 193 | $539.04 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 239 | $281.17 |
| 90677 | <1% | 375 | $241.23 | |
| 90670 | <1% | 2,153 | $140.00 | |
| 90700 | <1% | 462 | $122.50 | |
| 90633 | <1% | 1,422 | $122.50 | |
| 90686 | <1% | 1,696 | $72.87 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 117 | $70.75 |
| 96161 | <1% | 876 | $17.50 | |
| 36416 | <1% | 2,934 | $8.75 | |
| 90681 | 0% | 738 | $0.00 | |
| 99051 | 0% | 583 | $0.00 | |
| 99173 | 0% | 4,631 | $0.00 | |
| 90648 | 0% | 1,557 | $0.00 | |
| 90707 | 0% | 533 | $0.00 | |
| 90710 | 0% | 592 | $0.00 | |
| 90734 | 0% | 522 | $0.00 | |
| 90715 | 0% | 245 | $0.00 | |
| 90723 | 0% | 916 | $0.00 | |
| 90716 | 0% | 556 | $0.00 | |
| 90698 | 0% | 567 | $0.00 | |
| 90650 | 0% | 39 | $0.00 | |
| 90696 | 0% | 534 | $0.00 | |
| 90744 | 0% | 118 | $0.00 | |
| 90657 | 0% | 38 | $0.00 | |
| 90651 | 0% | 53 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 14 | $0.00 |
| 90697 | 0% | 45 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAQ, MUHAMMAD (CO-OWNER)
| Provider | Location | Paid |
|---|---|---|
| Delaware Diagnostic Imaging, P.A. | Wilmington, DE | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.